Question 14710 — diseases

Summary

Ms. Nathalie Colin-Oesterlé draws the attention of the Minister of Health, Families, Autonomy and People with Disabilities to the treatment of migraine in France and the persistent inequalities in access to innovative treatments. A chronic neurological pathology that is still too often trivialized because it is largely invisible, migraine nevertheless constitutes a major public health issue. In France, it concerns around 12% of the population adult, or several million people, with a significantly higher prevalence among women. It is now identified as the leading cause of disability among women under 50. The repercussions of this disease go far beyond just physical pain. Seizures can prevent daily, social or professional activity. Patients frequently report a profound alteration of their quality of life. Psychological comorbidities are also common, including anxiety, depression or sleep disorders. In this context, the arrival of new targeted therapeutic classes, notably anti-CGRP antibodies, constitutes a major advance for patients who have failed traditional disease-modifying treatments. These medications have demonstrated their effectiveness and tolerance in the prevention of severe migraines and are recommended by learned societies in patients with forms resistant to existing treatments. However, France today appears to be an exception in Europe: while these treatments are reimbursed or accessible in many neighboring countries, their cost remains largely the responsibility of patients when they are prescribed in the city. This situation creates significant inequalities of access, particularly in depending on the level of income or place of residence, with certain large metropolises concentrating the majority of issues. More broadly, late access to diagnosis also constitutes a major problem: the average time before diagnosis exceeds seven years and a third of patients have never consulted a health professional for their migraine. She therefore asks him what measures the Government is considering to adapt the conditions access to migraine treatments and thereby reduce the inequalities suffered by patients.

Machine translation from French. The official text remains authoritative.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

No documents linked.

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.